212 Participants Needed

Genetic Testing for Bleeding Disorders

(GT4BD Trial)

Recruiting at 2 trial locations
JG
MC
Overseen ByMegan Chaigneau, RN
Age: Any Age
Sex: Any
Trial Phase: Phase < 1
Sponsor: Queen's University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether early genetic testing can diagnose individuals with suspected inherited bleeding disorders more quickly and accurately. Researchers aim to determine if this approach results in faster diagnoses and proves cost-effective compared to standard testing methods. Participants will either receive early genetic testing alongside standard tests or follow the standard testing path, which may include genetic testing after a year. Ideal candidates are new patients with unusual bleeding patterns and either a family history of bleeding or a severe personal bleeding history. As an Early Phase 1 trial, this research focuses on understanding the role of early genetic testing in diagnosing bleeding disorders, offering participants a chance to contribute to groundbreaking medical advancements.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you are taking medications known to cause bleeding, you may be excluded from participating.

What prior data suggests that this genomic testing is safe for diagnosing inherited bleeding disorders?

Research has shown that genetic testing for inherited bleeding disorders is generally safe and well-tolerated. This testing examines genes to identify changes that might explain a bleeding problem. So far, no serious side effects from the testing itself have been reported.

The main goal is to obtain accurate results and interpret them correctly, aiding doctors in making better treatment decisions. Although genetic testing is new in some areas, it has been safely used in others, helping to identify conditions early and plan care. Participation in this trial involves testing considered safe based on current knowledge.12345

Why are researchers excited about this trial?

Researchers are excited about the genetic testing for bleeding disorders trial because it has the potential to revolutionize how these conditions are diagnosed. Unlike the standard diagnostic methods, which often involve a series of blood tests and medical history evaluations, early genomic testing can quickly identify specific genetic mutations responsible for bleeding disorders. This faster and more precise approach could lead to earlier interventions and personalized treatment plans, ultimately improving patient outcomes. By incorporating genomic testing into the diagnostic pathway, there's a hope to reduce the time and uncertainty patients often face when trying to understand their condition.

What evidence suggests that early genomic testing is effective for diagnosing inherited bleeding disorders?

Research has shown that early genetic testing in the diagnosis process can better identify inherited bleeding disorders. In this trial, participants in the "Early Genomic Testing Diagnostic Pathway" arm will receive early genomic testing alongside standard diagnostic testing. Traditional tests diagnose only about 30% of these cases and often overlook less common disorders. Genetic testing provides more accurate diagnoses, particularly for patients with unusual symptoms. This method not only increases the number of correct diagnoses but also accelerates the process. Therefore, early genetic testing is considered a promising tool for faster and more accurate diagnosis of bleeding disorders.16789

Who Is on the Research Team?

PD

Paula D James, MD, FRCPC

Principal Investigator

Queen's University

Are You a Good Fit for This Trial?

This trial is for patients with suspected inherited bleeding disorders who haven't been diagnosed after initial tests. It's open to those referred to Hematology and requires participants not yet having a confirmed diagnosis of their condition.

Inclusion Criteria

I am seeing a doctor because I have abnormal bleeding.
I have a history of abnormal bleeding, confirmed by a specialist.

Exclusion Criteria

I have a bleeding condition due to medication or liver/kidney disease.
I have been diagnosed with a hereditary bleeding disorder.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Diagnostic Testing

Participants undergo standard diagnostic testing with or without early genomic testing

1 year
Multiple visits as needed for diagnostic testing

Follow-up

Participants are monitored for diagnostic outcomes and health-related quality of life

1 year
Regular follow-up visits to assess outcomes

Economic Analysis

Economic implications and cost-effectiveness of genomic testing are analyzed

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • Genetic testing for inherited bleeding disorders
Trial Overview The study is examining if early genomic testing can help diagnose inherited bleeding disorders faster and more effectively compared to standard care. Participants are randomly assigned to either receive early genomic testing along with standard diagnostic tests or just the standard tests, with a later option for genomic testing.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Early Genomic Testing Diagnostic PathwayExperimental Treatment1 Intervention
Group II: Standard Diagnostic PathwayActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Queen's University

Lead Sponsor

Trials
382
Recruited
122,000+

Queen's University

Lead Sponsor

Kingston Health Sciences Centre

Lead Sponsor

Trials
312
Recruited
112,000+

The Ottawa Hospital

Collaborator

Trials
97
Recruited
64,000+

Unity Health Toronto

Collaborator

Trials
572
Recruited
470,000+

Citations

Genomic testing for bleeding disorders (GT4BD)First-line testing will effectively diagnose approximately 30% of new referrals, skewed towards identification of von Willebrand disease and ...
How genetic advances are being translated into improved ...Significant advances have been made in incorporating genetic testing to improve the diagnostic outcomes for patients with inherited bleeding disorders. The ...
How genetic advances are being translated into improved ...Significant advances have been made in incorporating genetic testing to improve the diagnostic outcomes for patients with inherited bleeding disorders. The ...
Bleeding Disorder/Coagulopathy PanelBlueprint Genetics' Bleeding Disorder/Coagulopathy Panel Is ideal for patients with a clinical suspicion of an inherited bleeding disorder.
5.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40246558/
Genomic testing for bleeding disorders (GT4BD)We will evaluate an early genomic testing strategy for the diagnosis of newly referred patients with a suspected inherited bleeding disorder.
Demystifying Genetic Testing for Bleeding DisordersGenetic testing also can be a valuable tool in guiding treatment decisions in patients who experience "spontaneous bleeding or who have no family history of ...
GNBLC - Overview: Bleeding Disorders, Comprehensive ...This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 25 genes associated with a variety of hereditary bleeding ...
Strengths and limitations of high‐throughput sequencing ...This review will outline some of the challenges that geneticists and experts in clinical hemostasis face when implementing high‐throughput sequencing (HTS) for ...
Genetic Testing for Inherited Conditions 2025-09-20 updated ...Genetic testing for inherited conditions includes single gene testing and applies to individuals, including pregnancies, which are clinically symptomatic for a ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security